

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# ClouDr Group Limited

## 智雲健康科技集團\*

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 9955)

### INSIDE INFORMATION POSITIVE PROFIT ALERT FOR THE YEAR ENDING DECEMBER 31, 2022

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and the potential investors that based on the preliminary assessment of the unaudited consolidated management accounts for the eleven months ended November 30, 2022 of the Group (the “**Management Accounts**”), as well as other relevant information currently available to the Board, the Group expects:

- (i) its revenue for the year ending December 31, 2022 to be between approximately RMB2,700 million to RMB3,100 million, representing an increase of approximately 53.7% to 76.5% year over year; and
- (ii) its adjusted net loss (non-IFRS measure)<sup>1</sup> for the year ending December 31, 2022 to be between approximately RMB290 million and RMB350 million, representing a reduction of approximately 21.2% to 34.7% year over year.

<sup>1</sup> We define “adjusted net loss (non-IFRS measure)” as loss for the relevant period and adding back (i) change in fair value of financial liabilities, (ii) share-based compensation expenses, (iii) listing expenses, and (iv) issuance cost of financial liability at fair value through profit or loss.

Based on information currently available to the Board, the expected significant year over year decrease in adjusted net loss is primarily attributable to (1) the strong and continued business growth as a result of the virtuous cycle established through our hospital-first strategy, which led to the expansion of the Group's network of hospitals and pharmacies, (2) the improved operating leverage as a result of the high customer stickiness with high recurring purchases, (3) more efficient research and development as a result of enhanced industry know-how and matured products, and (4) the improved efficiency in administrative expenses as a result of the operating leverage and effective cost control.

Shareholders and potential investors are advised that the Group's growth and financial performance in December 2022 remain subject to various factors, among others, the market conditions which may affect the Group's business.

As at the date of this announcement, the Group has not yet prepared its consolidated management accounts for the month ending December 31, 2022, and has not commenced the preparation of the consolidated financial results of the Group for the year ending December 31, 2022. The information contained in this announcement is therefore only based on a preliminary review of the Management Accounts and other relevant information currently available to the Board. Such Management Accounts have neither been confirmed nor audited by the Company's independent auditor, nor reviewed by the audit committee of the Company. As such, the actual annual results of the Group for the year ending December 31, 2022 may be different from what is disclosed in this announcement. Shareholders and potential investors are therefore advised to read carefully the annual results announcement of the Company for the year ending December 31, 2022, which is expected to be published on or before March 31, 2023. The Company will publish further announcement(s) in accordance with the Listing Rules as and when appropriate.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**ClouDr Group Limited**  
**Kuang Ming**  
*Chairman, Executive Director and  
Chief Executive Officer*

Hong Kong, December 6, 2022

*As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.*

\* *For identification purpose only*